Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF < sup > V600E < /sup > -Mutated Anaplastic Thyroid Carcinoma
Conclusions: Our results show that in BRAFm-ATC, addition of pembrolizumab to dabrafenib/trametinib may significantly prolong survival. Surgical resection of the primary tumor after initial BRAF-targeted therapy in selected patients may provide further survival benefit. However, conclusions are limited by the retrospective nature of the study. Additional prospective data are needed to confirm this observation.PMID:38226606 | DOI:10.1089/thy.2023.0573
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Authors: Sarah Hamidi Priyanka C Iyer Ramona Dadu Maria K Gule-Monroe Anastasios Maniakas Mark E Zafereo Jennifer R Wang Naifa L Busaidy Maria E Cabanillas Source Type: research
More News: Cancer & Oncology | Carcinoma | Endocrinology | Hepatitis | Immunotherapy | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Study | Thyroid | Thyroid Cancer